SCHEMBL6474044

SCHEMBL6474044

Cc1cccc(-c2ccc(OC(C)CNS(=O)(=O)C(C)C)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 10/20 0.48
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP3 P08254 1/20 0.40
MMP7 P09237 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
MMP14 P50281 1/20 0.40
GRIA1 P42261 1/20 0.39
GRIA2 P42262 1/20 0.39
GRIA3 P42263 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
NR1D1 P20393 1/20 0.37
KDM1A O60341 1/20 0.36
MTNR1A P48039 2/20 0.35
MTNR1B P49286 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474389 0.87 GRIA4 (0.62) GRIA4PPARGPPARAGRIA1GRIA2
SCHEMBL6475291 0.87 GRIA4 (0.62) GRIA4GRIA1GRIA2GRIA3MTNR1A
SCHEMBL6482318 0.87 GRIA4 (0.53) GRIA4GRIA1GRIA2GRIA3MTNR1A
SCHEMBL6479537 0.86 GRIA4 (0.47) GRIA4MMP1MMP2MMP3MMP7
SCHEMBL6474213 0.86 MTNR1A (0.48) GRIA4NR1D1MTNR1AMTNR1B
SCHEMBL6474261 0.86 GRIA4 (0.47) GRIA4MMP1MMP2MMP3MMP7
SCHEMBL6474424 0.86 GRIA4 (0.49) GRIA4GRIA1GRIA2GRIA3KDM1A
SCHEMBL6481818 0.85 KDM1A (0.52) GRIA4GRIA1GRIA2GRIA3KDM1A
SCHEMBL6474047 0.84 PPARG (0.44) GRIA4PPARGPPARAMMP1MMP2
SCHEMBL6481269 0.84 GRIA4 (0.51) GRIA4GRIA1GRIA2GRIA3KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885PPARG 828/4885PPARA 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.